Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Tissue inhibitor of metalloproteinases (TIMPs; TIMP-1, -2, -3 and -4) are endogenous inhibitor for matrix metalloproteinases (MMPs) that are responsible for remodeling the extracellular matrix (ECM) and involved in migration, invasion and metastasis of tumor cells. Unlike under normal conditions, the imbalance between MMPs and TIMPs is associated with various diseased states. Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78. The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs. Because the TIMP-1glycosylation participate in the interaction, aberrant glycosylation of TIMP-1 presumably affects the interaction, thereby leading to pathogenic dysfunction in cancer cells. TIMP-1 has not only the cell proliferation activities but also anti-oncogenic properties. Cancer cells appear to utilize these bilateral aspects of TIMP-1 for cancer progression; an elevated TIMP-1 level exerts to cancer development via MMP-independent pathway during the early phase of tumor formation, whereas it is the aberrant glycosylation of TIMP-1 that overcome the high anti-proteolytic burden. The aberrant glycosylation of TIMP-1can thus be used as staging and/or prognostic biomarker in colon cancer. [BMB Reports 2012; 45(11): 623-628]
Abstract
Tissue inhibitor of metalloproteinases (TIMPs; TIMP-1, -2, -3 and -4) are endogenous inhibitor for matrix metalloproteinases (MMPs) that are responsible for remodeling the extracellular matrix (ECM) and involved in migration, invasion and metastasis of tumor cells. Unlike under normal conditions, the imbalance between MMPs and TIMPs is associated with various diseased states. Among TIMPs, TIMP-1, a 184-residue protein, is the only N-linked glycoprotein with glycosylation sites at N30 and N78. The structural analysis of the catalytic domain of human stromelysin-1 (MMP-3) and human TIMP-1 suggests new possibilities of the role of TIMP-1 glycan moieties as a tuner for the proteolytic activities by MMPs. Because the TIMP-1glycosylation participate in the interaction, aberrant glycosylation of TIMP-1 presumably affects the interaction, thereby leading to pathogenic dysfunction in cancer cells. TIMP-1 has not only the cell proliferation activities but also anti-oncogenic properties. Cancer cells appear to utilize these bilateral aspects of TIMP-1 for cancer progression; an elevated TIMP-1 level exerts to cancer development via MMP-independent pathway during the early phase of tumor formation, whereas it is the aberrant glycosylation of TIMP-1 that overcome the high anti-proteolytic burden. The aberrant glycosylation of TIMP-1can thus be used as staging and/or prognostic biomarker in colon cancer. [BMB Reports 2012; 45(11): 623-628]
참고문헌 (51)
- Bhowmick, N. A., "Stromal fibroblasts in cancer initiation and progression", Nature, 432, pp.332~337 (2004)
- Stetler-Stevenson, W. G., "Tumor cell interactions with the extracellular matrixduring invasion and metastasis", Annu. Rev. Cell Biol., 9, pp.541~573 (1993)
- Nagase, H., "Matrix metalloproteinases", J. Biol. Chem., 274, pp.21491~21494 (1999)
- Welgus, H. G., "The collagen substrate specificity of human skin fibroblast collagenase", J. Biol. Chem., 256, pp.9511~9515 (1981)
- Hasty, K. A., "The collagen substrate specificity of human neutrophilcollagenase", J. Biol. Chem., 262, pp.10048~10052 (1987)
- Birkedal-Hansen, H., "Matrix metalloproteinases: a review", Crit. Rev. Oral Biol. Med., 4, pp.197~250 (1993)
- Greene, J., "Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4", J. Biol. Chem., 271, pp.30375~30380 (1996)
- Laurent, G. J., "Pulmonary fibrosis and emphysema: connective tissue disorders of the lung", Eur. J. Clin. Investig., 14, pp.411~413 (1984)
- Gomis-Rueth, F., "Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1", Nature, 389, pp.77~81 (1997)
- Varki, A., "Biological roles of oligosaccharides: all of the theories are correct", Glycobiology, 3, pp.97~130 (1995)
- Moens, S., "Glycoproteins in prokaryotes", Arch. Microbiol., 168, pp.169~175 (1997)
- Daniels, M. A., "Sweet ‘n’ sour: the impact of differential glycosylation on T cell responses", Nat. Immunol., 3, pp.903~910 (2002)
- Dwek, M. V., "Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer", Proteomics, 1, pp.756~762 (2001)
- Freeze, H. H., "Update and perspectives on congenital disorders of glycosylation", Glycobiology, 11, pp.129R~143R (2001)
- Thaysen-Andersen, M., "Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases- 1", Biochim. Biophys. Acta, 1784, pp.455~463 (2008)
- Luparello, C., "Tissue inhibitor of metalloproteinases (TIMP-1) and proliferative behaviour of clonal breast cancer cells", Breast Cancer Res. Treat., 54, pp.235~244 (1999)
- Guedez, L., "In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1", J. Clin. Invest., 102, pp.2002~2010 (1998)
- Li, G., "Tissue inhibitor of metalloproteinases-1 inhibits apoptosis of human breast epithelial cells", Cancer Res., 59, pp.6267~6275 (1999)
- Jung, K., "What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase- 1 (TIMP-1) in blood?", Clin. Chim. Acta, 254, pp.97~100 (1996)
- Greene, J., "Molecular cloning and characterization of human tissue inhibitor of metalloproteinase4", J. Biol. Chem., 271, pp.30375~30380 (1996)
- Docherty, A. J., "Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity", Nature, 318, pp.66~69 (1985)
- Murphy, G., "The N-terminal domain of human tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity", Biochemistry, 30, pp.8097~8102 (1991)
- Huang, W., "Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinase-1 (TIMP-1) expressed at high yield in E. coli", FEBS Lett., 384, pp.155~161 (1996)
- Stahl, B., "The oligosaccharides of the Fe(III)-Zn(II) purple acid-phosphatase of the red kidney bean-determination of the structure by a combination of matrix-assisted laser-desorption ionization mass spectrometry and selective enzymatic degradation", Eur. J. Biochem., 220, pp.321~330 (1994)
- Mortz, E., "Mass spectrometric characterization of glycosylated interferon-variants separated by gel electrophoresis", Electrophoresis, 17, pp.925~931 (1996)
- Garner, B., "Structural elucidation of the Nand O-glycans of human apolipoprotein(a): role of O-glycans in conferring protease resistance", J. Biol. Chem., 276, pp.200~208 (2001)
- Larsen, M. R., "Characterization of gel-separated glycoproteins using two-step proteolytic digestion combined with sequential microcolumns and mass spectrometry", Mol. Cell. Proteomics, 4, pp.107~119 (2005)
- Bunkenborg, J., "Screening for N-glycosylated proteins by liquid chromatography mass spectrometry", Proteomics, 4, pp.454~465 (2004)
- Holten-Andersen, M. N., "Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer", Br. J. Cancer., 80, pp.495~503 (1999)
- Sutton, C. W., "Sitespecific characterization of glycoprotein carbohydrates by exoglycosidase digestion and laser desorption mass spectrometry", Anal. Biochem., 218, pp.34~46 (1994)
- Thaysen-Andersen, M., "Rapid and individualspecific glycoprofiling of a low-abundant N-glycosylated protein tissue inhibitor of metalloproteinases-1", Mol. Cell. Proteomics, 6, pp.638~647 (2007)
- Kim, Y. S., "Functional proteomics study reveals that N-acetylglucosaminyltransferase V reinforces the invasive", metastatic potential of colon cancer through aberrant glycosylation on tissue inhibitor of metalloproteinase- 1, 2008, pp.7, 1~14
- Whiteside, T. L., "The tumor microenvironment and its role in promoting tumor growth", Oncogene, 27, pp.5904~5912 (2008)
- Lu, P., "The extracellular matrix. A dynamic niche in cancer progression", J. Cell Biol., 196, pp.395~406 (2012)
- Jeong-Gu Kang, "Pros and cons of using aberrant glycosylation as companion biomarkers for therapeutics in cancer", BMB Reports, 44(12), pp.765~771 (2011), 생화학분자생물학회
- Levental, K. R., "Matrix cross-linking forces tumor progression by enhancing integrin signaling", Cell, 139, pp.891~906 (2009)
- Egeblad, M., "New functions for the matrix metalloproteinases in cancer progression", Nat. Rev. Cancer, 2, pp.161~174 (2002)
- Docherty, A. J., "Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity", Nature, 318, pp.66~69 (1985)
- Taube, M. E., "TIMP-1 regulation of cell cycle in human breast epithelialcells via stabilization of p27KIP1 protein", Oncogene, 25, pp.3041~3048 (2006)
- Bloomston, M., "TIMP-1 antisense gene transfection attenuates theinvasive potential of pancreatic cancer cells in vitro andinhibits tumor growth in vivo", Am. J. Surg., 189, pp.675~679 (2005)
- Rho, S. B., "TIMP-1 regulates cell proliferation by interacting with the ninth zinc finger domain of PLZF", J. Cell. Biochem., 101, pp.57~67 (2007)
- Fowell, A. J., "Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation", Biochem. Biophys. Res. Commun., 407, pp.277~282 (2011)
- Tsagaraki, I., "TIMP-1 interaction with v3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis", Cell Tissue Res., 342, pp.87~96 (2010)
- Davidsen, M. L., "TIMP-1 gene deficiency increases tumor cell sensitivity to chemotherapy- induced apoptosis", Br. J. Cancer, 95, pp.114~120 (2006)
- Khokha, R., "Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1", J. Natl. Cancer Inst., 86, pp.299~304 (1994)
- Martin, D. C., "Inhibition of SV40 T antigen- induced hepatocellular carcinoma in TIMP-1 transgenic mice", Oncogene, 13, pp.569~576 (1996)
- Aljada, I. S., "Up-regulation of the tissue inhibitor of metalloproteinase- 1 protein is associated with progression of human non-small cell lung cancer", J. Clin. Oncol., 22, pp.3218~3229 (2004)
- Korpi, J. T., "Expression of matrix metalloproteinases-2, -8, -13, -26 and tissue inhibitors of metalloproteinase-1 in human osteosarcoma", Surg. Oncol., 20, pp.e18~e22 (2011)
- Inagaki, D., "Overexpression of tissue inhibitor of metalloproteinase-1 gene correlates with poor outcomes in colorectal cancer", Anticancer Res., 30, pp.4127~4130 (2010)
- Kim, Y. S., "Overexpression and β-1,6-N-acetylglucosaminylation initiated aberrant glycosylation of TIMP-1", J. Biol. Chem., 287, pp.32467~32478 (2012)
- Ahn, Y. H., "Comparative Quantitation of Aberrant Glycoforms by Lectin-Based Glycoprotein Enrichment Coupled with Multiple-Reaction Monitoring Mass Spectrometry", ANALYTICAL CHEMISTRY, 82(11), pp.4441~4447 (2010), AMER CHEMICAL SOC